Capsel R L, Olsen S C, Cheville N F, Thoen C O
Intervet, Inc., Bacteriology Research and Development, 902 Sugar Grove Ave., IA 50063, USA.
Biologicals. 2000 Dec;28(4):209-15. doi: 10.1006/biol.2000.0258.
Brucella abortus strain RB51 (SRB51) is a new cattle vaccine that is approved for use in the U.S. for prevention of brucellosis. At the present time, other countries are implementing or considering the use of SRB51 vaccine in their brucellosis control programs. In the current study, the effect of three stabilizing media, two fill volumes (1 and 3 ml), and three storage temperatures (-25, 4 and 25 degrees C) on the viability of lyophilized SRB51 over a 52 week period was determined. The effects of three concentrations of bacteria (5 x 10(8), 1 x 10(9), or 5 x 10(9) cfu/ml) and two storage temperatures (4 or 25 degrees C) on viability of liquid SRB51 vaccine were also determined. For lyophilized strain RB51 vaccine, fill volume did not influence viability (P> 0.05) during lyophilization. Although fill volume did not influence viability during storage in World Health Organization (WHO) media or media containing both WHO and Lactose Salt (LS) media, 1 ml fill volumes of SRB51 in LS media had greater (P< 0.05) viability when compared to 3 ml fill volumes. Lyophilized SRB51 vaccine stored at 25 degrees C had a more rapid decline in viability (P< 0.05) when compared to vaccine stored at -25 or 4 degrees C. With the exception of the 3-ml fill volumes of LS media, all three stabilizing media were similar in maintaining viability of SRB51 at -25 degrees C storage temperatures. However, when compared to WHO or WHO/LS media, stabilization in LS media was associated with a more rapid decline in viability during storage at 4 or 25 degrees C (P< 0.05). Initial SRB51 concentration in liquid vaccine did not influence (P> 0.05) viability during storage at 4 or 25 degrees C. When compared to liquid SRB51 vaccine stored at 25 degrees C, storage at 4 degrees C was associated with a slower decline in viability (P< 0.05) during 12 weeks of storage. Biochemical and morphological characteristics of SRB51 were stable under the storage conditions utilized in the present study. This study suggests that viability of SRB51 can be readily maintained during storage as a lyophilized or liquid brucellosis vaccine.
布鲁氏菌流产菌株RB51(SRB51)是一种新型牛用疫苗,已获美国批准用于预防布鲁氏菌病。目前,其他国家正在其布鲁氏菌病防控计划中实施或考虑使用SRB51疫苗。在本研究中,测定了三种稳定培养基、两种灌装体积(1毫升和3毫升)以及三种储存温度(-25℃、4℃和25℃)对冻干SRB51在52周期间活力的影响。还测定了三种细菌浓度(5×10⁸、1×10⁹或5×10⁹cfu/ml)和两种储存温度(4℃或25℃)对液体SRB51疫苗活力的影响。对于冻干的RB51菌株疫苗,灌装体积在冻干过程中不影响活力(P>0.05)。尽管灌装体积在世界卫生组织(WHO)培养基或含有WHO和乳糖盐(LS)的培养基中储存期间不影响活力,但与3毫升灌装体积相比,LS培养基中1毫升灌装体积的SRB51具有更高的(P<0.05)活力。与储存在-25℃或4℃的疫苗相比,储存在25℃的冻干SRB51疫苗活力下降更快(P<0.05)。除了3毫升灌装体积的LS培养基外,在-25℃储存温度下,所有三种稳定培养基在维持SRB51活力方面相似。然而,与WHO或WHO/LS培养基相比,在4℃或25℃储存期间,在LS培养基中稳定化与活力下降更快相关(P<0.05)。液体疫苗中初始SRB51浓度在4℃或25℃储存期间不影响(P>0.05)活力。与储存在25℃的液体SRB51疫苗相比,在4℃储存12周期间,活力下降更慢(P<0.05)。在本研究使用的储存条件下,SRB51的生化和形态特征稳定。本研究表明,作为冻干或液体布鲁氏菌病疫苗储存期间,SRB51的活力可以很容易地维持。